.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Farmers Insurance
US Army
Harvard Business School
Johnson and Johnson
Queensland Health
McKinsey
Novartis
Healthtrust
Express Scripts

Generated: June 23, 2017

DrugPatentWatch Database Preview

Loratadine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for loratadine and what is the scope of loratadine patent protection?

Loratadine
is the generic ingredient in eleven branded drugs marketed by Perrigo, Bayer Healthcare Llc, Taro, Teva, Sandoz, Perrigo Pharma Intl, Marksans Pharma, Wockhardt, Silarx, Pfizer, Ranbaxy Labs Ltd, Sun Pharm Inds Ltd, Mylan, Apotex Inc, Taro Pharm, and Actavis Labs Fl Inc, and is included in thirty-six NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Loratadine has thirty-one patent family members in twenty-eight countries.

There are thirty-nine drug master file entries for loratadine. One hundred and thirty suppliers are listed for this compound.

Summary for Generic Name: loratadine

Tradenames:11
Patents:2
Applicants:16
NDAs:36
Drug Master File Entries: see list39
Suppliers / Packagers: see list130
Bulk Api Vendors: see list83
Clinical Trials: see list38
Patent Applications: see list6,151
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:loratadine at DailyMed

Pharmacology for Ingredient: loratadine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan
LORATADINE
loratadine
TABLET;ORAL075790-001Nov 7, 2008OTCNoNo► Subscribe► Subscribe
Sun Pharm Inds Ltd
LORATADINE
loratadine
TABLET;ORAL076134-001Aug 18, 2003OTCNoNo► Subscribe► Subscribe
Bayer Healthcare Llc
CLARITIN
loratadine
CAPSULE;ORAL021952-001Jun 16, 2008OTCYesYes► Subscribe► Subscribe
Bayer Healthcare Llc
CLARITIN-D
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL019670-002Nov 27, 2002OTCYesYes► Subscribe► Subscribe
Bayer Healthcare Llc
CHILDREN'S CLARITIN
loratadine
TABLET, CHEWABLE;ORAL021891-001Aug 23, 2006OTCYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: loratadine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc
CLARITIN
loratadine
SYRUP;ORAL020641-002Nov 27, 20024,863,931*PED► Subscribe
Bayer Healthcare Llc
CLARITIN
loratadine
TABLET;ORAL019658-002Nov 27, 20024,863,931*PED► Subscribe
Bayer Healthcare Llc
CLARITIN REDITABS
loratadine
TABLET, ORALLY DISINTEGRATING;ORAL020704-002Nov 27, 20024,659,716*PED► Subscribe
Bayer Healthcare Llc
CLARITIN
loratadine
TABLET;ORAL019658-002Nov 27, 20024,659,716*PED► Subscribe
Bayer Healthcare Llc
CLARITIN
loratadine
SYRUP;ORAL020641-002Nov 27, 20024,659,716*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: loratadine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,514,520 Stabilized antihistamine syrup► Subscribe
6,939,550 Stabilized antihistamine syrup► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: loratadine

Country Document Number Estimated Expiration
Colombia5011119► Subscribe
Gulf Cooperation Council0000330► Subscribe
Egypt23908► Subscribe
Taiwan589197► Subscribe
Canada2333528► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LORATADINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
01C/013Belgium► SubscribePRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
C/GB01/012United Kingdom► SubscribePRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Julphar
Deloitte
Fish and Richardson
UBS
Merck
Healthtrust
Baxter
Accenture
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot